Lately, I have been taking what feels like an excessive number of sick days, both from work and from day-to-day activities. In the past couple of years, it’s taken time to accept that I must prioritize my body’s needs and slow down or rest when needed has…
A greater decline in lung function prior to treatment start may lead idiopathic pulmonary fibrosis (IPF) patients to stop using Ofev (nintedanib), as might older age, a real-world study from the United Kingdom found. “No predominant reason for discontinuation was identified in this group,” its researchers wrote, but it’s…
Genkyotex’s anti-fibrotic candidate GKT831 appears to be safe and hold therapeutic activity in an ongoing Phase 2 trial in patients with primary biliary cholangitis, an autoimmune-triggered fibrotic disease of the liver. These positive interim results support the development of GKT831 as a possible treatment of other fibrotic diseases,…
Since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in April 2016, I have enjoyed connecting with other patients living with this life-threatening lung disease. For the most part, hearing others’ stories has given me comfort, hope, and encouragement. I believe that the benefits of connecting with my…
BML‐111, a potent activator of the natural anti-inflammatory lipoxin A4 receptor, protects lungs from fibrosis by inhibiting fibroblast activation and decreasing the levels of inflammatory signaling molecules, a mouse study shows. The study “BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo” was…
I don’t know about you, but I’m continually aware of my limited time on this earth. Using my time wisely is very important to me. I’ve been working on several goals that have been a challenge to finish. I thought I’d share one I recently completed and what…
Results from the long-term PASSPORT clinical study are consistent with the known safety profile of Esbriet (pirfenidone), further strengthening the safety of the therapy in patients with idiopathic pulmonary fibrosis (IPF). After authorization by the European Medicine Agency (EMA), it was suggested that a large, long-term post-authorization study be conducted…
As I reflect on this past month, I am happy to share that October has been filled with many good times and memories for my loved ones and me. As we’re only a couple of months away from wrapping up 2018, I look forward to reflecting on this…
Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first participant has now received the therapy. GLPG1205 is an anti-inflammatory small molecule that specifically inhibits GPR84, a protein that promotes…
Treatment with Ofev (nintedanib) offers less clinical benefit to patients with severe idiopathic pulmonary fibrosis (IPF) than to those with mild-to-moderate disease, but does improve outcomes if these patients are able to continue on treatment over the longer term, a new study shows. Controlling the therapy’s side effects will be essential…
Get regular updates to your inbox.
